Group 1 - Weihai Guangtai reported a net profit of 83.32 million yuan for the first half of 2025, a year-on-year decrease of 22.41%, while total revenue reached 1.425 billion yuan, an increase of 10.91% [1] - Haowei Group expects a net profit increase of 39.43% to 49.67% for the first half of 2025, estimating a profit range of 1.906 billion to 2.046 billion yuan [1] - Tengda Construction won a bid for a project worth 118 million yuan, with a construction period of 500 calendar days [1] Group 2 - Shanda Power plans to use up to 520 million yuan of idle raised funds for cash management, investing in safe and liquid products with a term not exceeding 12 months [3] - Rundu Co., Ltd. received approval for the listing application of its chemical raw material drug, which is suitable for surgical treatment in adults and children over one month old [4] - Zhongyuan Qihua's subsidiary's clinical trial application for a drug aimed at treating pulmonary fibrosis has been accepted [4] Group 3 - Shanghai Xiba plans to establish a joint venture with Yuyuan Rare Earth, focusing on advanced materials for lithium-ion solid-state batteries, with a registered capital of 200 million yuan [6] - Aorite's senior management plans to reduce their holdings by up to 62,500 shares, accounting for 0.02% of the company's total equity [7] - Yipin Hong's subsidiary's clinical trial application for a new oral drug for endometriosis has been accepted [8] Group 4 - Haya Pharmaceutical plans to lease idle assets covering 22,671.39 square meters for a period of 10 years [9] - Southern Precision Engineering applied for a credit limit of 50 million yuan from a bank for operational purposes [11] - Jindawei's subsidiary established a joint venture with a registered capital of 5 million yuan, focusing on the sale of food additives and health products [12] Group 5 - Gaode Infrared signed a product order contract worth 307 million yuan, expected to account for 11.46% of the company's audited revenue for 2024 [13] - Xichang Electric will implement a low valley electricity price policy starting September 1, 2025, which is expected to reduce net profit by approximately 5.55 million yuan [14] - Huyou Pharmaceutical's first subject has been dosed in a Phase I clinical trial for a drug targeting advanced solid tumors [16] Group 6 - Chuanheng Co., Ltd. received a patent for a dust removal system in mining operations [17] - Spring Wind Power's application for issuing convertible bonds has been accepted by the Shanghai Stock Exchange [18] - Liuyao Group plans to repurchase shares worth between 100 million and 200 million yuan [19] Group 7 - Baiyun Electric has obtained a commitment letter for a stock repurchase loan of up to 18 million yuan [20] - Tonghe Pharmaceutical received a patent for a method of preparing an intermediate for a migraine treatment drug [21] - Tainkang's subsidiary's Phase II clinical trial for a drug for vitiligo has shown significant efficacy and safety [23] Group 8 - Yuhua Tian's secretary and deputy general manager resigned for personal reasons [24] - Heizhima's controlling shareholder is planning a change in control, leading to a temporary suspension of stock trading [25] - Keda Li's subsidiary completed a capital increase, raising its registered capital to 700 million yuan [26] Group 9 - Fangda Special Steel's shareholder plans to reduce holdings by up to 1% of the company's shares [28] - ST Pava's director is under investigation for alleged embezzlement, but the company's operations remain normal [29] - Jiachuan Video's controlling shareholder is planning a change in control, resulting in a temporary stock suspension [32] Group 10 - Danhua Technology will change its stock name to Jinmei Technology starting August 7, 2025, due to a relocation of its registered office [33] - Morning Wind Technology's shareholder plans to reduce holdings by up to 1% of the company's shares [34] - Leshan Electric will adjust residential gas prices starting September 1, 2025, which is expected to increase gross profit by approximately 2.7 million yuan [35] Group 11 - SAIC Motor reported a total vehicle sales of 337,500 units in July 2025, a year-on-year increase of 34.22%, with significant growth in new energy vehicle sales [36] - LIGONG Navigation's shareholders plan to reduce holdings by up to 3% of the company's shares [37] - United Imaging's employee stock ownership platform plans to reduce holdings by up to 1.62% of the company's shares [38] Group 12 - Beiqi Blue Valley's subsidiary reported a 6.38% decline in sales in July 2025 [39] - Watson Bio's clinical research application for an mRNA vaccine has been accepted [40]

证券代码：600645 证券简称：中源协和 公告编号：2025-032 中源协和细胞基因工程股份有限公司（以下简称"公司"）全资子公司武汉 光谷中源药业有限公司于 2025 年 8 月 1 日取得国家药品监督管理局药品审评中 心（CDE）签发的关于 VUM02 注射液临床试验申请《受理通知书》，受理号为 CXSL2500651。现对有关信息公告如下： 中源协和细胞基因工程股份有限公司 关于全资子公司药品临床试验申请取得受理通知书 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、药品基本信息 药品名称：VUM02 注射液 剂型：注射剂 规格：5E7 个细胞（10 mL）/袋 注册分类：治疗用生物制品 1 类 申请事项：境内生产药品注册临床试验 申请人：武汉光谷中源药业有限公司 受理号：CXSL2500651 二○二五年八月五日 VUM02 注射液（人脐带源间充质基质细胞注射液）是我司自主研发的冷冻 保存型细胞制剂，是由经筛选的健康新生儿脐带组织通过体外分离、扩增、收获、 冻存后制备的人脐带源间充质基质细胞（UC-MS ...

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the Clinical Trial Application Acceptance Notice from the National Medical Products Administration (NMPA) for VUM02 injection on August 1, 2025, indicating progress in the development of this new drug [1] Group 1 - The VUM02 injection is a cryopreserved cell preparation developed independently by the company, derived from selected healthy newborn umbilical cord tissue [1] - The clinical trial aims to expand the indications for VUM02 injection to include the treatment of pulmonary fibrosis following pneumonia [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the Clinical Trial Application Acceptance Notice from the National Medical Products Administration (NMPA) for VUM02 injection on August 1, 2025, marking a significant step in the development of a new treatment for post-pneumonia pulmonary fibrosis [1] Group 1 - VUM02 injection is an autologous cryopreserved cell preparation derived from umbilical cord mesenchymal stem cells (UC-MSC) obtained from healthy newborns [1] - The clinical application aims to treat post-pneumonia pulmonary fibrosis, a condition for which no similar cell therapies are currently available globally [1] - The development of VUM02 is supported by previous clinical research data from studies on COVID-19 and idiopathic pulmonary fibrosis [1]

Core Viewpoint - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of VUM02 injection from the National Medical Products Administration (NMPA) on August 1, 2025, marking a significant step in the development of a new treatment for post-pneumonia pulmonary fibrosis [1] Group 1 - VUM02 injection is an autologous cryopreserved cell preparation derived from selected healthy newborn umbilical cord tissue, aimed at treating post-pneumonia pulmonary fibrosis [1] - There are currently no similar cell drugs approved globally for the treatment of post-pneumonia pulmonary fibrosis, with the fastest progressing similar drugs still in early research stages [1] - The application for this indication is supported by previous clinical research data from COVID-19 and idiopathic pulmonary fibrosis Phase I clinical trials [1]

Core Points - Zhongyuan Union (600645.SH) announced that its wholly-owned subsidiary, Wuhan Guanggu Zhongyuan Pharmaceutical Co., Ltd., received the acceptance notice for the clinical trial application of VUM02 injection from the National Medical Products Administration on August 1, 2025 [2] - VUM02 injection is a self-developed cryopreserved cell preparation by Zhongyuan Union, aimed at treating post-pneumonia pulmonary fibrosis [2] Company Summary - The company is advancing its research and development efforts with the VUM02 injection, indicating a focus on innovative treatments in the pharmaceutical sector [2] - The approval for clinical trials represents a significant milestone for the company, potentially enhancing its product pipeline and market position [2]

Group 1 - The company held its 20th temporary board meeting on July 28, 2025, where it approved the acquisition of 25% equity in Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. from Shanghai Yanlin Biotechnology Co., Ltd. [1][12] - The acquisition was approved with 7 votes in favor, 0 against, and 0 abstentions, and the related directors recused themselves from the vote [2][5][12] - The transaction is classified as a related party transaction due to the controlling relationship between the parties involved [8][14] Group 2 - The total assessed value of 100% equity in Shanghai Zhongyuan Jisheng is RMB 15.2783 million, with the agreed transfer price for the 25% stake set at RMB 3,819,575 [9][10][20] - The transaction does not constitute a major asset restructuring and does not require shareholder approval [9][13] - The company aims to enhance operational efficiency and increase resource investment in adult health cell storage business through this acquisition [30][31] Group 3 - The company plans to establish its East China headquarters in Shanghai and has signed a real estate lease agreement with Shanghai Yanlin Biotechnology Co., Ltd. [34][36] - The total rent for the leased property is RMB 12,239,910, with a rental period from August 1, 2025, to July 31, 2028 [35][36] - The rental price is set at RMB 6 per day per square meter, with options for payment that include discounts for upfront payments [36][49] Group 4 - The lease agreement includes provisions for shared use of certain areas and specifies that the company will not incur additional business dependencies on related parties [56][57] - The company’s independent directors have reviewed and approved the lease agreement, confirming that it aligns with the company's strategic planning and does not harm shareholder interests [57][58]

Core Points - The company held its 20th temporary board meeting on July 28, 2025, via communication voting, with all directors ensuring the accuracy and completeness of the announcement [1][2] - The board approved the proposal regarding the acquisition of partial equity held by shareholders of Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd., which was reviewed and passed by the independent directors [1] - The board also approved a proposal for a real estate lease contract with Shanghai Yanlin Biotechnology Co., Ltd., which was similarly reviewed and passed by the independent directors [2] Summary by Category - **Board Meeting Details** - The meeting was conducted on July 28, 2025, with notifications sent to all directors on July 23, 2025 [1] - The voting was deemed valid as the required directors attended the meeting [1] - **Equity Acquisition Proposal** - The proposal for acquiring partial equity from Shanghai Zhongyuan Jisheng Cell Technology Co., Ltd. was approved [1] - The independent directors held a special meeting to review this proposal prior to the board meeting [1] - **Real Estate Lease Agreement** - The board approved a real estate lease contract with Shanghai Yanlin Biotechnology Co., Ltd. [2] - Similar to the equity acquisition, this proposal was also reviewed by independent directors before approval [2]

Core Viewpoint - The company plans to establish its East China headquarters in Shanghai by signing a real estate lease agreement with Shanghai Yanlin Biotechnology Co., Ltd, which includes provisions for shared and free usage of certain areas [1][2][11] Summary by Sections 1. Overview of Related Transactions - The company intends to lease a property located at No. 5, Lane 276, Luding Road, Putuo District, Shanghai, from Shanghai Yanlin Biotechnology Co., Ltd for its East China headquarters [2][3] - The property consists of five floors, with the first floor partially provided for free as a product experience center and the second floor shared for customer reception [2][3] 2. Lease Details - The lease includes the 5th floor with an area of 825 square meters and the 3rd and 4th floors with a total area of 1,660 square meters, with a rental period from August 1, 2025, to July 31, 2028 [2][3] - The rental rate is set at RMB 6 per day per square meter, resulting in an annual rent of RMB 5,442,150 [2][3] - The company has chosen to pay the rent in a lump sum, receiving a 10% discount, leading to a total rent of RMB 12,239,910 [3][8] 3. Related Party Information - Shanghai Yanlin Biotechnology Co., Ltd is controlled by the same actual controller as the company, Chen Chunmei, thus constituting a related party transaction [3][4] - The company has not engaged in related transactions exceeding RMB 30 million in the past 12 months, and this transaction does not require shareholder approval [3][11] 4. Purpose and Impact of the Transaction - The lease aligns with the company's long-term strategic planning and business development needs, facilitating resource optimization and market expansion in East China [10][11] - The rental price is deemed fair and reasonable, ensuring no harm to shareholders, particularly minority shareholders [10][11] 5. Approval Process - The independent directors unanimously approved the lease agreement, confirming its alignment with the company's strategic goals and fair pricing [11][12] - The board meeting held on July 28, 2025, saw all attending directors vote in favor of the transaction, with related directors abstaining from the vote [11]

证券代码：600645 证券简称：中源协和 公告编号：2025-030 ? 上海延藜公司为公司实际控制人陈春梅女士控制的企业，根据《上海证 券交易所股票上市规则》的规定，本次交易构成关联交易。 ? 本次交易不构成重大资产重组 ? 本次关联交易无需提交公司股东大会审议。 ? 至本次关联交易为止，过去 12 个月与同一关联人以及与不同关联人进行 的交易类别相关的关联交易（日常关联交易除外）的累计次数为 1 次：协和干细 胞基因工程有限公司继续委托天津市红磡物业经营管理有限公司负责天津市华 苑 产 业 园 区 梅 苑 路 12 号区 域内的 物 业 管理服 务 ，合 同 期服 务费用 总计 为 关于收购子公司上海中源济生细胞科技有限公司股 东所持部分股权暨关联交易的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ? 交易简要内容：为提高经营决策效率，继续加大对成人健康细胞存储业 务的资源投入，公司拟以自有资金收购上海延藜生物技术有限公司（以下简称"上 海延藜公司"）持有的上海中源济生细胞科技有限公司（ ...